<DOC>
	<DOCNO>NCT00187525</DOCNO>
	<brief_summary>This 52-week , multicenter , open label trial memantine ( Namenda ) frontotemporal lobar degeneration ( FTLD ) . The goal determine safety tolerability FDA-approved medication Alzheimer 's Disease patient FTLD . Secondary outcome measure include cognitive battery , rating scale activity daily live neuropsychiatric symptom . All patient receive FDA-approved dose medication Alzheimer 's disease .</brief_summary>
	<brief_title>A 52 Week Open Label Trial Memantine Frontotemporal Lobar Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Neary et al . Criteria Frontotemporal Lobar Degeneration Age 40 80 CDR &lt; 3 MMSE &gt; 15 English Speaking Study Partner Concurrent use antipsychotic drug acetylcholinesterase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>